RBC Capital Maintains Outperform on Biogen, Raises Price Target to $272
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $256 to $272.
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $256 to $272.